Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11401 - 11425 of 11753 in total
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
Matched Description: … Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. …
Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer).
Investigational
Matched Description: … Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing …
MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).
Investigational
Matched Description: … MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK …
QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene.
Investigational
Matched Description: … QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant …
PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme. This class of compounds has been shown to prevent both abnormal...
Investigational
Matched Description: … PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed ... PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically …
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Investigational
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced …
Sulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It is available in Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of coccidiosis.
Vet approved
Matched Description: … Sulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It …
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
Investigational
Matched Description: … Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation …
CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.
Investigational
Matched Description: … CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed …
An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)
Experimental
Matched Description: … It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6- …
IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Investigational
Matched Description: … It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific …
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. …
Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.
Experimental
Matched Description: … Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. …
Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine. Racivir is a 50:50 mixture of emtricitabine and its positive enantiomer. Racivir has been used in trials studying the prevention of HIV Infections.
Investigational
Matched Description: … Racivir is a 50:50 mixture of [emtricitabine] and its positive enantiomer. …
SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. …
Mibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies).
Investigational
Matched Description: … Mibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics …
Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).
Investigational
Matched Description: … Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination …
Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides. It is under investigation for the treatment of hyperphenylalaninemia.
Investigational
Matched Description: … Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing …
Investigational
Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Experimental
Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
Investigational
Matched Description: … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis …
Displaying drugs 11401 - 11425 of 11753 in total